Tag: Patients
Published Study Finds 9/10 Chronic Wound Patients Likely to Have Received More Appropriately Triaged Care with Information from the MolecuLight i

Published Study Finds 9/10 Chronic Wound Patients Likely to Have Received More Appropriately Triaged Care with Information from the MolecuLight i

Study Highlights the Utility of Bacterial Fluorescence Imaging to Provide Real-Time Information to Clinicians on a Wound's Bacterial Burden that Significantly Impacted ...

Lees verder
Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skippin

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skippin

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications ...

Lees verder
Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with

Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with

ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media DARMSTADT, Germany, June 3, 2019 /PRNewswire/ -- -- ...

Lees verder
Beckman Coulter's New Procalcitonin Assay Helps Physicians Accurately Identify Patients at Risk for Progression to Septic Shock

Beckman Coulter's New Procalcitonin Assay Helps Physicians Accurately Identify Patients at Risk for Progression to Septic Shock

Access PCT strengthens industry's most extensive portfolio of in-vitro diagnostic testing for sepsis identification and management BREA, California, March 26, 2019 ...

Lees verder
Regulators, Physicians, Patients to WHO: A Harmonized Biologic Naming Protocol is Important to Patient Safety; Please Act Now

Regulators, Physicians, Patients to WHO: A Harmonized Biologic Naming Protocol is Important to Patient Safety; Please Act Now

WASHINGTON, Oct. 23, 2018 /PRNewswire/ -- A whitepaper released today by the Alliance for Safe Biologic Medicines calls on the World Health Organization (WHO) to implement a ...

Lees verder
Kyowa Kirin Presents Data at EORTC-Cutaneous Lymphoma Task Force Meeting Showing Significantly Improved Quality of Life for Patients With Mycosis

Kyowa Kirin Presents Data at EORTC-Cutaneous Lymphoma Task Force Meeting Showing Significantly Improved Quality of Life for Patients With Mycosis

TOKYO, September 28, 2018 /PRNewswire/ -- First oral presentation of Quality of Life data from the phase III trial (MAVORIC), the largest randomised trial in MF and SS - the ...

Lees verder
Experts Call for Improved Identification of 'High Burden' Rosacea Patients in Everyday Practice

Experts Call for Improved Identification of 'High Burden' Rosacea Patients in Everyday Practice

PARIS, September 14, 2018 /PRNewswire/ -- Additional analysis of global survey data reveals quality of life is impacted by several factors extending beyond severity of rosacea ...

Lees verder
European Hematology Association: iNNOVATE Study: Ibrutinib Plus Rituximab for Patients With Waldenström's Macroglobulinemia

European Hematology Association: iNNOVATE Study: Ibrutinib Plus Rituximab for Patients With Waldenström's Macroglobulinemia

STOCKHOLM, June 16, 2018 /PRNewswire/ -- Waldenström's Macroglobulinemia (WM) is a rare type of blood cancer. Since WM is rare, it is difficult to conduct large clinical ...

Lees verder
SI-BONE, Inc. Announces Publication of 3-Year Long-term Prospective Outcomes Including Randomized Controlled Trial Data on 103 Patients Post SI J

SI-BONE, Inc. Announces Publication of 3-Year Long-term Prospective Outcomes Including Randomized Controlled Trial Data on 103 Patients Post SI J

SI-BONE, Inc. Announces Publication of 3-Year Long-term Prospective Outcomes Including Randomized Controlled Trial Data on 103 Patients Post SI Joint Fusion with Triangular ...

Lees verder
Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in

Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in

OSAKA, Japan, February 16, 2018 /PRNewswire/ -- New clinical study also provides data for Entyvio(R) in inducing complete mucosal healing and endoscopic remission, ...

Lees verder
BizPress.nl